On Friday, NetEase, Inc (ADR) (NASDAQ:NTES)’s shares declined -5.87% to $126.04.
NetEase, Inc. (NTES), one of China’s leading Internet and online game services providers, declared its unaudited financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Financial Results
Revenues
Total revenues for the second quarter of 2015 were RMB4,833.1 million (US$779.5 million), contrast to RMB3,885.2 million and RMB2,951.9 million for the preceding quarter and the second quarter of 2014, respectively.
Revenues from online games were RMB3,849.9 million (US$621.0 million) for the second quarter of 2015, contrast to RMB3,104.2 million and RMB2,336.5 million for the preceding quarter and the second quarter of 2014, respectively.
Revenues from advertising services were RMB477.7 million (US$77.0 million) for the second quarter of 2015, contrast to RMB332.6 million and RMB389.1 million for the preceding quarter and the second quarter of 2014, respectively.
Revenues from e-mail, e-commerce and others were RMB505.5 million (US$81.5 million) for the second quarter of 2015, contrast to RMB448.4 million and RMB226.3 million for the preceding quarter and the second quarter of 2014, respectively.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries. The company’s 3D printers transform data input from the format generated by 3D design software, CAD software, or 3D scanning and sculpting devices to printed parts using integrated, engineered plastic, metal, nylon, rubber, wax, and composite print materials.
William Lyon Homes (NYSE:WLH)’s shares dropped -5.29% to $23.83.
William Lyon Homes (WLH) declared that, subject to market conditions, entities associated with Luxor Capital Group, LP (“Luxor”) intend to offer 2,000,000 shares of the Company’s Class A Common Stock in a registered public offering. The Company will not sell any shares in this offering or receive any portion of the proceeds from this offering. Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the projected offering.
The offering of these securities is being made following a shelf registration statement which was declared effective by the Securities and Exchange Commission (“SEC”) on March 20, 2014. A preliminary prospectus supplement regardingthe offering has been filed with the SEC. Copies of the preliminary prospectus supplement related to the offering and accompanying prospectus may be obtained by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York, 10010, or by telephone at (800) 221-1037.
William Lyon Homes, together with its auxiliaries, designs, constructs, markets, and sells single-family detached and attached homes in California, Arizona, Nevada, Colorado, Washington, and Oregon. The company sells its homes primarily to entry-level, first-time move-up and second-time move-up homebuyers under the Village Homes and Polygon Northwest Homes brands through in-house commissioned sales personnel and outside brokers.
At the end of Friday’s trade, The Medicines Company (NASDAQ:MDCO)‘s shares dipped -0.07% to $30.27.
The Medicines Company (MDCO) declared its financial results for the second quarter and first half of 2015.
Second-Quarter 2015 Financial Summary
Worldwide net revenue was $90.5 million for the second quarter of 2015 contrast to $183.8 million in the second quarter of 2014. Worldwide Angiomax®/Angiox® (bivalirudin) revenue was $65.6 million in the second quarter of 2015 contrast to $163.1 million in the second quarter of 2014, with revenue in the United States decreasing to $60.5 million in the second quarter of 2015 from $152.2 million in the second quarter of 2014. Recothrom®, Thrombin topical (Recombinant) sales were $15.9 million contrast to $16.3 million in the second quarter of 2014. Other products counting Cleviprex® (clevidipine), Argatroban for Injection, 50 mg per mL, Minocin® (minocycline) for injection, Orbactiv® (oritavancin) and PreveLeakTM Surgical Sealant recorded sales of $9.0 million during second quarter of 2015 contrast to $4.4 million in the second quarter of 2014. Not taking into account Angiomax, the company recorded 20% higher net revenue during the second quarter of 2015 contrast to the second quarter of 2014.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Radius Health Inc (NASDAQ:RDUS), ended its Friday’s trading session with 0.36% gain, and closed at $66.86.
Radius Health, Inc. (RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis in addition to other serious endocrine-mediated diseases, counting hormone responsive metastatic breast cancer, stated its financial results for the second quarter ended June 30, 2015, and offered recent corporate highlights. As of June 30, 2015, Radius had $224.0 million in cash, cash equivalents and marketable securities, and on July 28, 2015, raised about $323.8 million of net proceeds in a follow-on public offering of its common stock.
Recent Corporate Highlights
Follow On Public Offering
On July 28, 2015, Radius accomplished a public offering whereby it sold 4,054,054 shares of common stock at a public offering price of $74.00 per share, for aggregate proceeds, net of underwriting discounts, commissions, and estimated offering costs, of about $281.5 million. The underwriters purchased an additional 608,108 shares by exercising their option to purchase additional shares granted to them in connection with the offering. As a result of the public offering and exercise of the underwriters’ option to purchase additional shares, Radius received aggregate proceeds, net of underwriting discounts, commissions, and estimated offering costs of about $323.8 million. Radius plans to use these additional funds to expand the development of RAD1901 for potential use in metastatic breast cancer in combination with other approved therapies, to fund the continued development of the optimized abaloparatide transdermal patch and related manufacturing capabilities, and to continue to build the commercial infrastructure, inventory and manufacturing capabilities necessary for commercialization of abaloparatide-SC following regulatory approval.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has accomplished Phase II clinical trial, which is used to enhance bone mineral density.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
